DATATOP: A decade of neuroprotective inquiry
Identifieur interne : 000194 ( Main/Corpus ); précédent : 000193; suivant : 000195DATATOP: A decade of neuroprotective inquiry
Auteurs : ShoulsonSource :
- Annals of Neurology [ 0364-5134 ] ; 1998-09.
Abstract
In 1987, the DATATOP clinical trial was initiated to examine the benefits of deprenyl (selegiline) and α‐tocopherol in slowing the progression of Parkinson's disease (PD). After 14 ± 6 (mean ± SD) months of controlled observation, deprenyl 10 mg/day was found to significantly delay the time until enough disability developed to warrant the initiation of levodopa therapy. This effect was largely sustained during the overall 8.2 years of observation, including open‐label deprenyl treatment and a second treatment randomization to continue deprenyl or switch to placebo. There were no accompanying benefits of deprenyl in postponing levodopa‐related adverse effects or extending life. α‐Tocopherol produced no benefits. The 2.1% per year mortality rate of the DATATOP cohort was remarkably low, about the same as an age‐matched population without PD. Neuroprotective therapy remains an elusive goal for the experimental therapeutics of PD. Advances in understanding pathogenesis, a robust pipeline of rational treatments, and the advent of valid and reliable biologic markers hold promise in the coming decade for developing and achieving neuroprotective therapies for PD.
Url:
DOI: 10.1002/ana.410440724
Links to Exploration step
ISTEX:B1EF59AC84F0685F3556CF98C6A1472513B16C66Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">DATATOP: A decade of neuroprotective inquiry</title><author><name sortKey="Shoulson" sort="Shoulson" uniqKey="Shoulson" last="Shoulson">Shoulson</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, NY.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B1EF59AC84F0685F3556CF98C6A1472513B16C66</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/ana.410440724</idno><idno type="url">https://api.istex.fr/document/B1EF59AC84F0685F3556CF98C6A1472513B16C66/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000194</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">DATATOP: A decade of neuroprotective inquiry</title><author><name sortKey="Shoulson" sort="Shoulson" uniqKey="Shoulson" last="Shoulson">Shoulson</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, NY.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-09">1998-09</date><biblScope unit="volume">44</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="supplement">1</biblScope><biblScope unit="page" from="S160">S160</biblScope><biblScope unit="page" to="S166">S166</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">B1EF59AC84F0685F3556CF98C6A1472513B16C66</idno><idno type="DOI">10.1002/ana.410440724</idno><idno type="ArticleID">ANA410440724</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In 1987, the DATATOP clinical trial was initiated to examine the benefits of deprenyl (selegiline) and α‐tocopherol in slowing the progression of Parkinson's disease (PD). After 14 ± 6 (mean ± SD) months of controlled observation, deprenyl 10 mg/day was found to significantly delay the time until enough disability developed to warrant the initiation of levodopa therapy. This effect was largely sustained during the overall 8.2 years of observation, including open‐label deprenyl treatment and a second treatment randomization to continue deprenyl or switch to placebo. There were no accompanying benefits of deprenyl in postponing levodopa‐related adverse effects or extending life. α‐Tocopherol produced no benefits. The 2.1% per year mortality rate of the DATATOP cohort was remarkably low, about the same as an age‐matched population without PD. Neuroprotective therapy remains an elusive goal for the experimental therapeutics of PD. Advances in understanding pathogenesis, a robust pipeline of rational treatments, and the advent of valid and reliable biologic markers hold promise in the coming decade for developing and achieving neuroprotective therapies for PD.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Dr Shoulson MD</name><affiliations><json:string>Department of Neurology, University of Rochester, Rochester, NY.</json:string></affiliations></json:item></author><articleId><json:string>ANA410440724</json:string></articleId><language><json:string>eng</json:string></language><abstract>In 1987, the DATATOP clinical trial was initiated to examine the benefits of deprenyl (selegiline) and α‐tocopherol in slowing the progression of Parkinson's disease (PD). After 14 ± 6 (mean ± SD) months of controlled observation, deprenyl 10 mg/day was found to significantly delay the time until enough disability developed to warrant the initiation of levodopa therapy. This effect was largely sustained during the overall 8.2 years of observation, including open‐label deprenyl treatment and a second treatment randomization to continue deprenyl or switch to placebo. There were no accompanying benefits of deprenyl in postponing levodopa‐related adverse effects or extending life. α‐Tocopherol produced no benefits. The 2.1% per year mortality rate of the DATATOP cohort was remarkably low, about the same as an age‐matched population without PD. Neuroprotective therapy remains an elusive goal for the experimental therapeutics of PD. Advances in understanding pathogenesis, a robust pipeline of rational treatments, and the advent of valid and reliable biologic markers hold promise in the coming decade for developing and achieving neuroprotective therapies for PD.</abstract><qualityIndicators><score>7.048</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1173</abstractCharCount><pdfWordCount>4996</pdfWordCount><pdfCharCount>32131</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>171</abstractWordCount></qualityIndicators><title>DATATOP: A decade of neuroprotective inquiry</title><corporate><json:item><name>Parkinson Study Group</name></json:item></corporate><genre><json:string>article</json:string></genre><host><volume>44</volume><publisherId><json:string>ANA</json:string></publisherId><pages><total>7</total><last>S166</last><first>S160</first></pages><issn><json:string>0364-5134</json:string></issn><issue>S1</issue><subject><json:item><value>Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8249</json:string></eissn><title>Annals of Neurology</title><doi><json:string>10.1002/(ISSN)1531-8249</json:string></doi></host><publicationDate>1998</publicationDate><copyrightDate>1998</copyrightDate><doi><json:string>10.1002/ana.410440724</json:string></doi><id>B1EF59AC84F0685F3556CF98C6A1472513B16C66</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/B1EF59AC84F0685F3556CF98C6A1472513B16C66/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/B1EF59AC84F0685F3556CF98C6A1472513B16C66/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/B1EF59AC84F0685F3556CF98C6A1472513B16C66/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">DATATOP: A decade of neuroprotective inquiry</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>1998</date></publicationStmt><notesStmt><note>Public Health Service - No. NS24778;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">DATATOP: A decade of neuroprotective inquiry</title><author><orgName>Parkinson Study Group</orgName></author><author><persName><surname>Shoulson</surname></persName><roleName type="degree">Dr</roleName><note type="correspondence"><p>Correspondence: Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 212, Rochester, NY 14620</p></note><affiliation>Department of Neurology, University of Rochester, Rochester, NY.</affiliation></author></analytic><monogr><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="pISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><idno type="DOI">10.1002/(ISSN)1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-09"></date><biblScope unit="volume">44</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="supplement">1</biblScope><biblScope unit="page" from="S160">S160</biblScope><biblScope unit="page" to="S166">S166</biblScope></imprint></monogr><idno type="istex">B1EF59AC84F0685F3556CF98C6A1472513B16C66</idno><idno type="DOI">10.1002/ana.410440724</idno><idno type="ArticleID">ANA410440724</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1998</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>In 1987, the DATATOP clinical trial was initiated to examine the benefits of deprenyl (selegiline) and α‐tocopherol in slowing the progression of Parkinson's disease (PD). After 14 ± 6 (mean ± SD) months of controlled observation, deprenyl 10 mg/day was found to significantly delay the time until enough disability developed to warrant the initiation of levodopa therapy. This effect was largely sustained during the overall 8.2 years of observation, including open‐label deprenyl treatment and a second treatment randomization to continue deprenyl or switch to placebo. There were no accompanying benefits of deprenyl in postponing levodopa‐related adverse effects or extending life. α‐Tocopherol produced no benefits. The 2.1% per year mortality rate of the DATATOP cohort was remarkably low, about the same as an age‐matched population without PD. Neuroprotective therapy remains an elusive goal for the experimental therapeutics of PD. Advances in understanding pathogenesis, a robust pipeline of rational treatments, and the advent of valid and reliable biologic markers hold promise in the coming decade for developing and achieving neuroprotective therapies for PD.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1998-09">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-2">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/B1EF59AC84F0685F3556CF98C6A1472513B16C66/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley component found"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8249</doi><issn type="print">0364-5134</issn><issn type="electronic">1531-8249</issn><idGroup><id type="product" value="ANA"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ANNALS OF NEUROLOGY">Annals of Neurology</title><title type="short">Ann Neurol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="70"><doi origin="wiley" registered="yes">10.1002/ana.v44.1s</doi><titleGroup><title type="supplementTitle">Cell Death and Neuroprotection in Parkinson's Disease</title></titleGroup><numberingGroup><numbering type="journalVolume" number="44">44</numbering><numbering type="journalIssue">S1</numbering><numbering type="supplement" number="1">1</numbering></numberingGroup><coverDate startDate="1998-09">September 1998</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="24" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ana.410440724</doi><idGroup><id type="unit" value="ANA410440724"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="publisher">Copyright © 1998 Wiley‐Liss, Inc.</copyright><eventGroup><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.2.9 mode:FullText" date="2014-02-20"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.2.9 mode:FullText" date="2014-02-20"></event><event type="firstOnline" date="2014-02-21"></event><event type="publishedOnlineFinalForm" date="2014-02-21"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">S160</numbering><numbering type="pageLast">S166</numbering></numberingGroup><correspondenceTo>Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 212, Rochester, NY 14620</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANA.ANA410440724.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="0"></count></countGroup><titleGroup><title type="main" xml:lang="en">DATATOP: A decade of neuroprotective inquiry</title><title type="short" xml:lang="en">DATATOP and Neuroprotection</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr</honorifics><givenNames>Ira</givenNames><familyName>Shoulson</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author"><groupName>Parkinson Study Group</groupName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Rochester, Rochester, NY.</unparsedAffiliation></affiliation></affiliationGroup><fundingInfo><fundingAgency>Public Health Service</fundingAgency><fundingNumber>NS24778</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>In 1987, the DATATOP clinical trial was initiated to examine the benefits of deprenyl (selegiline) and α‐tocopherol in slowing the progression of Parkinson's disease (PD). After 14 ± 6 (mean ± SD) months of controlled observation, deprenyl 10 mg/day was found to significantly delay the time until enough disability developed to warrant the initiation of levodopa therapy. This effect was largely sustained during the overall 8.2 years of observation, including open‐label deprenyl treatment and a second treatment randomization to continue deprenyl or switch to placebo. There were no accompanying benefits of deprenyl in postponing levodopa‐related adverse effects or extending life. α‐Tocopherol produced no benefits. The 2.1% per year mortality rate of the DATATOP cohort was remarkably low, about the same as an age‐matched population without PD. Neuroprotective therapy remains an elusive goal for the experimental therapeutics of PD. Advances in understanding pathogenesis, a robust pipeline of rational treatments, and the advent of valid and reliable biologic markers hold promise in the coming decade for developing and achieving neuroprotective therapies for PD.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>DATATOP: A decade of neuroprotective inquiry</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>DATATOP and Neuroprotection</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>DATATOP: A decade of neuroprotective inquiry</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr</namePart><namePart type="family">Shoulson</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Rochester, Rochester, NY.</affiliation><description>Correspondence: Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 212, Rochester, NY 14620</description><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>Parkinson Study Group</namePart><description>Department of Neurology, University of Rochester, Rochester, NY.</description></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1998-09</dateIssued><copyrightDate encoding="w3cdtf">1998</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent></physicalDescription><abstract lang="en">In 1987, the DATATOP clinical trial was initiated to examine the benefits of deprenyl (selegiline) and α‐tocopherol in slowing the progression of Parkinson's disease (PD). After 14 ± 6 (mean ± SD) months of controlled observation, deprenyl 10 mg/day was found to significantly delay the time until enough disability developed to warrant the initiation of levodopa therapy. This effect was largely sustained during the overall 8.2 years of observation, including open‐label deprenyl treatment and a second treatment randomization to continue deprenyl or switch to placebo. There were no accompanying benefits of deprenyl in postponing levodopa‐related adverse effects or extending life. α‐Tocopherol produced no benefits. The 2.1% per year mortality rate of the DATATOP cohort was remarkably low, about the same as an age‐matched population without PD. Neuroprotective therapy remains an elusive goal for the experimental therapeutics of PD. Advances in understanding pathogenesis, a robust pipeline of rational treatments, and the advent of valid and reliable biologic markers hold promise in the coming decade for developing and achieving neuroprotective therapies for PD.</abstract><note type="funding">Public Health Service - No. NS24778; </note><relatedItem type="host"><titleInfo><title>Annals of Neurology</title></titleInfo><titleInfo type="abbreviated"><title>Ann Neurol.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0364-5134</identifier><identifier type="eISSN">1531-8249</identifier><identifier type="DOI">10.1002/(ISSN)1531-8249</identifier><identifier type="PublisherID">ANA</identifier><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><detail type="issue"><caption>no.</caption><number>S1</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>1</number></detail><extent unit="pages"><start>S160</start><end>S166</end><total>7</total></extent></part></relatedItem><identifier type="istex">B1EF59AC84F0685F3556CF98C6A1472513B16C66</identifier><identifier type="DOI">10.1002/ana.410440724</identifier><identifier type="ArticleID">ANA410440724</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1998 Wiley‐Liss, Inc.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000194 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000194 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:B1EF59AC84F0685F3556CF98C6A1472513B16C66
|texte= DATATOP: A decade of neuroprotective inquiry
}}
| This area was generated with Dilib version V0.6.23. |  |